{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:36:23Z","timestamp":1780875383679,"version":"3.54.1"},"reference-count":67,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To review the wide variety of treatment modalities available for choroidal neovascularization secondary to the presumed ocular histoplasmosis syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A literature search was performed to review the multitude of studies conducted to investigate the efficacy and safety of treatment modalities available for choroidal neovascularization secondary to the presumed ocular histoplasmosis syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Each treatment modality is reviewed, with the studies summarized and presented to support or refute the method of treatment. Two case reports are presented to demonstrate the treatment regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This is a comprehensive review of the treatment modalities available to address choroidal neovascularization secondary to the presumed ocular histoplasmosis syndrome. Investigators will continue to strive toward higher efficacy and safety with future innovations in the field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000002352","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T08:58:55Z","timestamp":1541062735000},"page":"226-234","source":"Crossref","is-referenced-by-count":5,"title":["MANAGEMENT OF NEOVASCULAR OCULAR HISTOPLASMOSIS"],"prefix":"10.1097","volume":"39","author":[{"given":"Kevin J.","family":"Blinder","sequence":"first","affiliation":[{"name":"The Retina Institute, St. Louis, Missouri; and Ophthalmology and Visual Sciences, Washington University, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1001\/archopht.121.11.1551","article-title":"Detection of Histoplasma capsulatum DNA in lesions of chronic ocular histoplasmosis syndrome","volume":"121","author":"Spencer","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00004397-197501530-00018","article-title":"Koch's postulates and experimental ocular histoplasmosis","volume":"15","author":"Wong","year":"1975","journal-title":"Int Ophthalmol Clin"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/09273940701375428","article-title":"Presumed ocular histoplasmosis syndrome in India","volume":"15","author":"Sinha","year":"2007","journal-title":"Ocul Immunol Inflamm"},{"key":"R4-20230816","first-page":"371","article-title":"The status of presumed ocular histoplasmosis: including a report of a survey","volume":"64","author":"Asbury","year":"1966","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0002-9394(73)90648-X","article-title":"Photocoagulation of disciform macular lesions in the ocular histoplasmosis syndrome","volume":"75","author":"Maumenee","year":"1973","journal-title":"Am J Ophthalmol"},{"key":"R6-20230816","first-page":"45","article-title":"Argon laser photocoagulation in ocular histoplasmosis syndrome","volume":"16","author":"Patz","year":"1976","journal-title":"Int Ophthalmol Clin"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0161-6420(82)34727-2","article-title":"A comparative study of argon and krypton laser. Photocoagulation in the treatment of presumed ocular histoplasmosis syndrome","volume":"89","author":"Sabates","year":"1982","journal-title":"Ophthalmology"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/archopht.1983.01040020349002","article-title":"Argon laser photocoagulation for ocular histoplasmosis. Results of a randomized clinical trial","volume":"101","year":"1983","journal-title":"Arch Ophthalmol"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/archopht.1986.01050170084028","article-title":"Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials","volume":"104","year":"1986","journal-title":"Arch Ophthalmol"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1001\/archopht.1991.01080080069030","article-title":"Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1001\/archopht.1987.01060110045029","article-title":"Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis: results of a randomized clinical trial","volume":"105","year":"1987","journal-title":"Arch Ophthalmol"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/archopht.1994.01090160076025","article-title":"Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials","volume":"112","year":"1994","journal-title":"Arch Ophthalmol"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archopht.1995.01100020074032","article-title":"The influence of treatment extent on the visual acuity of eyes treated with Krypton laser for juxtafoveal choroidal neovascularization","volume":"113","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/archopht.1991.01080090044025","article-title":"Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration: results of a randomized clinical trial","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archopht.1993.01090010021006","article-title":"Laser treatment for subfoveal neovascular membranes in ocular histoplasmosis syndrome: results of a pilot randomized clinical trial","volume":"111","author":"Fine","year":"1993","journal-title":"Arch Ophthalmol"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archopht.1995.01100010058021","article-title":"Laser photocoagulation for neovascular lesions nasal to the fovea. Results from clinical trials for lesions secondary to ocular histoplasmosis or idiopathic causes","volume":"113","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9394(14)76888-6","article-title":"Surgical removal of subfoveal neovascularization in the presumed ocular histoplasmosis syndrome","volume":"111","author":"Thomas","year":"1991","journal-title":"Am J Ophthalmol"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0161-6420(92)31888-3","article-title":"Surgical management of subfoveal choroidal neovascularization","volume":"99","author":"Thomas","year":"1992","journal-title":"Ophthalmology"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0161-6420(94)31172-9","article-title":"Visual results after surgical removal of subfoveal choroidal neovascular membranes","volume":"101","author":"Thomas","year":"1994","journal-title":"Ophthalmology"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.1997.01100160161004","article-title":"Submacular surgery for subfoveal choroidal neovascular membranes in patients with presumed ocular histoplasmosis","volume":"115","author":"Berger","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0161-6420(96)30566-6","article-title":"Managing recurrent neovascularization after subfoveal surgery in presumed ocular histoplasmosis syndrome","volume":"103","author":"Melberg","year":"1996","journal-title":"Ophthalmology"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0161-6420(97)30367-4","article-title":"Surgical removal of subfoveal choroidal neovascularization in presumed ocular histoplasmosis: stability of early visual results","volume":"104","author":"Holekamp","year":"1997","journal-title":"Ophthalmology"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/S0161-6420(98)99024-8","article-title":"Surgical removal of extensive peripapillary choroidal neovascularization associated with presumed ocular histoplasmosis syndrome","volume":"105","author":"Atebara","year":"1998","journal-title":"Ophthalmology"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0002-9394(00)00729-7","article-title":"Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: I. Ophthalmic outcomes submacular surgery trials pilot study report number 1","volume":"130","author":"Bressler","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archopht.122.11.1597","article-title":"Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: I. Ophthalmic findings from a randomized clinical trial: submacular surgery trials (SST) group H trial: SST Report No. 9","volume":"122","author":"Hawkins","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R26-20230816","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1001\/archopht.122.11.1616","article-title":"Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: II. Quality-of-life findings from a randomized clinical trial: SST group H trial: SST Report No. 10","volume":"122","author":"Hawkins","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1001\/archopht.126.12.1626","article-title":"Surgical removal vs observation for idiopathic or ocular histoplasmosis syndrome-associated subfoveal choroidal neovascularization: vision preference value scale findings from the randomized SST group H trial: SST Report No. 17","volume":"126","author":"Bass","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R28-20230816","first-page":"617","article-title":"Pathogenesis of disciform detachment of the neuroepithelium. III. Senile disciform macular degeneration","volume":"63","author":"Gass","year":"1967","journal-title":"Am J Ophthalmol"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00006982-199111030-00010","article-title":"Clinicopathologic studies of treated choroidal neovascular membranes. A review and report of two cases","volume":"11","author":"Green","year":"1991","journal-title":"Retina"},{"key":"R30-20230816","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0002-9394(98)00145-7","article-title":"Clinicopathologic correlations of surgically excised Type 1 and Type 2 submacular choroidal neovascular membranes","volume":"126","author":"Grossniklaus","year":"1998","journal-title":"Am J Ophthalmol"},{"key":"R31-20230816","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00055735-200006000-00005","article-title":"Update on surgical removal of choroidal neovascularization","volume":"11","author":"Rao","year":"2000","journal-title":"Curr Opin Ophthalmol"},{"key":"R32-20230816","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.survophthal.2015.02.005","article-title":"Ocular histoplasmosis syndrome","volume":"60","author":"Diaz","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"R33-20230816","first-page":"1","article-title":"Evolution of choroidal neovascularization due to presumed ocular histoplasmosis syndrome on multimodal imaging including optical coherence tomography angiography","author":"Liu","year":"2018","journal-title":"Case Rep Ophthalmol Med"},{"key":"R34-20230816","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/archopht.117.10.1329","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials\u2014TAP report","volume":"117","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"R35-20230816","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0161-6420(02)01103-X","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series","volume":"109","author":"Saperstein","year":"2002","journal-title":"Ophthalmology"},{"key":"R36-20230816","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ophtha.2004.02.014","article-title":"Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study","volume":"111","author":"Rosenfeld","year":"2004","journal-title":"Ophthalmology"},{"key":"R37-20230816","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00006982-200306000-00003","article-title":"Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome","volume":"23","author":"Busquets","year":"2003","journal-title":"Retina"},{"key":"R38-20230816","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00417-003-0734-5","article-title":"Long-term results after photodynamic therapy with verteporfin for choroidal neovascularization secondary to inflammatory chorioretinal diseases","volume":"241","author":"Wachtlin","year":"2003","journal-title":"Graefes Arch Exp Ophthalmol"},{"key":"R39-20230816","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/00006982-200412000-00004","article-title":"Photodynamic therapy of subfoveal and juxtafoveal choroidal neovascularization in ocular histoplasmosis syndrome: a retrospective case series","volume":"24","author":"Liu","year":"2004","journal-title":"Retina"},{"key":"R40-20230816","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/09273940590951124","article-title":"Photodynamic therapy for subfoveal classic choroidal neovascularization related to punctate inner choroidopathy (PIC) or presumed ocular histoplasmosis-like syndrome (POHS-like)","volume":"13","author":"Postelmans","year":"2005","journal-title":"Ocul Immunol Inflamm"},{"key":"R41-20230816","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S0161-6420(03)00466-4","article-title":"Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults","volume":"110","author":"Rogers","year":"2003","journal-title":"Ophthalmology"},{"key":"R42-20230816","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1001\/archopht.118.3.327","article-title":"A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes","volume":"118","author":"Sickenberg","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R43-20230816","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00006982-200501000-00003","article-title":"Photodynamic therapy for juxtafoveal choroidal neovascularization due to ocular histoplasmosis syndrome","volume":"25","author":"Shah","year":"2005","journal-title":"Retina"},{"key":"R44-20230816","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00006982-200501000-00004","article-title":"Photodynamic therapy with verteporfin for peripapillary choroidal neovascularization","volume":"25","author":"Rosenblatt","year":"2005","journal-title":"Retina"},{"key":"R45-20230816","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00004397-197501530-00022","article-title":"Therapy of chorioretinitis presumed to be caused by histoplasmosis","volume":"15","author":"Makley","year":"1975","journal-title":"Int Ophthalmol Clin"},{"key":"R46-20230816","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00004397-198302320-00012","article-title":"Corticosteroids in the treatment of ocular histoplasmosis","volume":"23","author":"Schlaege","year":"1983","journal-title":"Int Ophthalmol Clin"},{"key":"R47-20230816","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0002-9394(67)90032-3","article-title":"Presumed histoplasmic choroiditis","volume":"63","author":"Schlaegel","year":"1967","journal-title":"Am J Ophthalmol"},{"key":"R48-20230816","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0161-6420(84)34113-6","article-title":"Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome. Visual prognosis","volume":"91","author":"Olk","year":"1984","journal-title":"Ophthalmology"},{"key":"R49-20230816","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0002-9394(00)00520-1","article-title":"Choroidal neovascularization with granulomatous inflammation in ocular histoplasmosis syndrome","volume":"130","author":"Mann","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"R50-20230816","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/jop.1999.15.425","article-title":"Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization","volume":"15","author":"Martidis","year":"1999","journal-title":"J Ocul Pharmacol Ther"},{"key":"R51-20230816","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9394(03)00389-1","article-title":"Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome","volume":"136","author":"Rechtman","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R52-20230816","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ajo.2004.10.005","article-title":"The safety profile of long-term, high-dose intraocular corticosteroid delivery","volume":"139","author":"Holekamp","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R53-20230816","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s00417-007-0637-y","article-title":"Intravitreal bevacizumab as initial treatment for choroidal neovascularization associated with presumed ocular histoplasmosis syndrome","volume":"245","author":"Ad\u00e1n","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R54-20230816","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ajo.2007.12.030","article-title":"Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis","volume":"145","author":"Schadlu","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R55-20230816","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0b013e3181babdf1","article-title":"Intravitreal bevacizumab for choroidal neovascularization secondary to presume ocular histoplasmosis syndrome","volume":"29","author":"Ehrlich","year":"2009","journal-title":"Retina"},{"key":"R56-20230816","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ophtha.2010.04.016","article-title":"Ranibizumab for choroidal neovascularization secondary to causes other than age related macular degeneration: a phase I clinical trial","volume":"118","author":"Heier","year":"2011","journal-title":"Ophthalmology"},{"key":"R57-20230816","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/ICB.0b013e3182a48bcc","article-title":"Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization in ocular histoplasmosis","volume":"8","author":"Hu","year":"2014","journal-title":"Retin Cases Brief Rep"},{"key":"R58-20230816","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/IAE.0b013e318229b220","article-title":"Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome","volume":"32","author":"Nielsen","year":"2012","journal-title":"Retina"},{"key":"R59-20230816","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3928\/23258160-20121221-07","article-title":"Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis syndrome","volume":"44","author":"Ramaiya","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R60-20230816","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema the diabetic retinopathy clinical research network","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"key":"R61-20230816","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcjo.2015.11.007","article-title":"Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection","volume":"51","author":"Walia","year":"2016","journal-title":"Can J Ophthalmol"},{"key":"R62-20230816","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/IAE.0000000000001590","article-title":"Intravitreal aflibercept for choroidal neovascularization due to presumed ocular histoplasmosis syndrome. The HANDLE Study","volume":"38","author":"Toussaint","year":"2018","journal-title":"Retina"},{"key":"R63-20230816","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2165\/00002512-200724120-00002","article-title":"Combination therapy for choroidal neovascularisation","volume":"24","author":"Augustin","year":"2007","journal-title":"Drugs Aging"},{"key":"R64-20230816","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1097\/01.iae.0000247164.70376.91","article-title":"Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration","volume":"26","author":"Dhalla","year":"2006","journal-title":"Retina"},{"key":"R65-20230816","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/IAE.0b013e3180323de7","article-title":"Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone","volume":"27","author":"Augustin","year":"2007","journal-title":"Retina"},{"key":"R66-20230816","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/eye.2009.122","article-title":"Combined intravitreal anti-VEGF and verteporfin photodynamic therapy for juxtafoveal and extrafoveal choroidal neovascularization as an alternative to laser photocoagulation","volume":"24","author":"Han","year":"2010","journal-title":"Eye (Lond)"},{"key":"R67-20230816","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ophtha.2011.08.032","article-title":"Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis","volume":"119","author":"Cionni","year":"2012","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201902000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:53:02Z","timestamp":1775256782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201902000-00002"}},"subtitle":["Past and Present"],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002352","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}